UBS Knock-Out ABT/ DE000UL972F1 /
2024-05-03 9:36:55 AM | Chg.+0.020 | Bid9:36:55 AM | Ask9:36:55 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.450EUR | +4.65% | 0.450 Bid Size: 2,500 |
0.500 Ask Size: 2,500 |
Abbott Laboratories | 101.8561 USD | 2078-12-31 | Call |
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
GlobeNewswire
2023-09-06
Endexx Corporation Appoints Ahmed Itani to Director of Marketing of HYLA in The Middle East Region